Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

Phase 3

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

Sponsor:

DBV Technologies

Code:

NCT05741476

Conditions

Allergy, Peanut

Eligibility Criteria

Sex: All

Age: 4 - 7

Healthy Volunteers: Not accepted

Interventions

DBV712

Placebo

DBV712

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information